
A well-defined scientific and strategic approach is critical for buyers in this dealmaking setting.
Chief Strategy Officer, PharmaLex, a Cencora company
A well-defined scientific and strategic approach is critical for buyers in this dealmaking setting.
Amid shifting operating dynamics in recent years, demands for external expertise have fluctuated—leaving those arrangements that mix innovation and agility likely to win out in pharma decision-making.